Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dako, a developer of tissue-based cancer diagnostics, has entered into a collaboration with Osi Pharmaceuticals, a biotechnology company. Under the terms of agreement, Dako and Osi Pharmaceuticals will collaborate on developing a new cancer diagnostic test as a potential companion product for a cancer therapy.
Subscribe to our email newsletter
The new cancer diagnostic test is intended to identify patients more likely to benefit from a specific treatment. The collaboration will draw on Dako’s extensive experience within the development of cancer diagnostic tests and Osi Pharmaceuticals’s thorough knowledge in developing and commercializing novel pharmaceutical products.
Lars Holmkvist, CEO and president of Dako Denmark, said: “The future within oncology pharmacotherapy is in targeted therapies. Linking a drug with a diagnostic test is what you can call a triple win situation. Most importantly, the patient will receive relevant therapy from the start instead of a trial-and-error medication.
“Secondly, the pharmaceutical company may develop even more innovative and improved cancer therapies, thereby increasing the general health within society. Thirdly, Dako itself will continue to provide gold standard companion diagnostics to the market, thereby contributing to improve the overall healthcare costs.”